Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESMAIN Study of resminostat maintenance in advanced mycosis fungoides or Sézary syndrome
2016-000807-99Phase 2Unknown
- Sponsor
- 4SC AG
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in mycosis fungoides (MF), Sézary syndrome (SS) and cutaneous T-cell lymphoma (CTCL) comparing Resminostat maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
Resminostat
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on 2016-000807-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000807-99.